Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases
Julie Gehl(University of Copenhagen), Lluis M. Mir(Centre National de la Recherche Scientifique), P. Curatolo(Sapienza University of Rome), Joy Odili(St George’s University Hospitals NHS Foundation Trust), L Campana(University of Padua), Antonio Occhini(University of Pavia), Pietro Quaglino(Department of Medical Sciences), Giulia Bertino(University College Cork), Christian Kunte(München Klinik), Marco Benazzo(University of Pavia), Gregor Serša(University of Ljubljana), A. James P. Clover(University College Cork), Louise Wichmann Matthiessen(University of Copenhagen), Karin Dahlstrøm(University of Copenhagen), Declan M. Soden(University College Cork), Tobian Muir(James Cook University Hospital), Víctor Farricha(Instituto Português de Oncologia Francisco Gentil)
Cited by 387
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
|European Journal of Cancer|2017|449